Roche Reports Strong Sales Growth in Q1 2026

Roche achieved a 6% increase in group sales at constant exchange rates for Q1 2026, amounting to CHF 14.7 billion despite a 5% decrease in reported CHF due to Swiss franc appreciation. The pharmaceuticals division grew by 7% in constant rates, driven by strong demand for products addressing severe diseases. The company confirmed its full-year outlook and anticipates further growth in the pharmaceuticals and diagnostics sectors, backed by a diversified pipeline and continued advancements in treatment options.